Complete remission seven years after treatment for metastatic malignant melanoma.

Abstract

BACKGROUND:

In this study, the authors identified seven-year survivors after completion of the French multicenter Phase II trial of fotemustine for the treatment of metastatic malignant melanoma.

METHODS:

One hundred sixty-nine patients with metastatic malignant melanoma were included in this Phase II study. One hundred fifty-three patient records were evaluable with an overall response rate of 24.2%.

RESULTS:

Five of these patients are alive and in complete remission. One patient had a complete response after fotemustine administration and then relapsed. One patient had a partial response. Three patients had stable disease. These five patients underwent surgery for relapse or residual disease and subsequently achieved durable complete remission.

CONCLUSIONS:

Long term survival may be the outcome after surgical resection of residual metastatic melanoma after chemotherapy.

• Authors: T Petit, C Borel, O Rixe, M F Avril, A Monnier, B Giroux, M Weil, D Khayat
• Journal: Cancer (Cancer) Vol. 77 Issue 5 Pg. 900-2 (Mar 01 1996) ISSN: 0008-543X [Print] United States
• PMID: 8608481 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Antineoplastic Agents
• Nitrosourea Compounds
• Organophosphorus Compounds
• fotemustine

Topics

• Antineoplastic Agents (therapeutic use)
• Disease-Free Survival
• Follow-Up Studies
• Humans
• Lymph Nodes (surgery)
• Lymphatic Metastasis
• Melanoma (drug therapy, secondary)
• Nitrosourea Compounds (therapeutic use)
• Organophosphorus Compounds (therapeutic use)
• Remission Induction
• Splenic Neoplasms (secondary, surgery)